TY  - JOUR
AU  - Paiva, Bruno
AU  - Mateos, María Victoria
AU  - Sanchez-Abarca, Luis Ignacio
AU  - Puig, Noemi
AU  - Vidriales, María-Belén
AU  - López-Corral, Lucía
AU  - Corchete, Luis A
AU  - Hernandez, Miguel T
AU  - Bargay, Joan
AU  - de Arriba, Felipe
AU  - de la Rubia, Javier
AU  - Teruel, Ana-Isabel
AU  - Giraldo, Pilar
AU  - Rosiñol, Laura
AU  - Prosper, Felipe
AU  - Oriol, Albert
AU  - Hernández, José
AU  - Esteves, Graça
AU  - Lahuerta, Juan José
AU  - Bladé, Joan
AU  - Perez-Simon, Jose Antonio
AU  - San Miguel, Jesús F
AU  - Spanish Myeloma Group / Program Study and Treatment of Hematological Malignancies cooperative study groups
PY  - 2015
DO  - 10.1182/blood-2015-10-662320
UR  - http://hdl.handle.net/10668/9664
T2  - Blood
AB  - There is significant interest in immunotherapy for the treatment of high-risk smoldering multiple myeloma (SMM), but no available data on the immune status of this particular disease stage. Such information is important to understand the interplay...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biomarkers, Tumor
KW  - Cell Proliferation
KW  - Demography
KW  - Dexamethasone
KW  - Female
KW  - Humans
KW  - Immunophenotyping
KW  - Induction Chemotherapy
KW  - Killer Cells, Natural
KW  - Lenalidomide
KW  - Longitudinal Studies
KW  - Maintenance Chemotherapy
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Risk Factors
KW  - T-Lymphocytes
KW  - Thalidomide
TI  - Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
TY  - research article
VL  - 127
ER  -